pharma news today obesity drugs glp-1 today U.S. FDA | FDA issued its fastest approval for a novel drug (NME) since 2002, as part of the national priority voucher pilot program. ✔️ New GLP-1 Drug Market: the rapid
Description
As such, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) critically affect hepatic regeneration in rodent models
This is not about choosing one strategy over another
Obesity / chronic weight management is the fastest growing segment, driven by the escalation of world obesity and the growing body of evidence for the utility of GLP-1 therapies in weight loss
Experimental studies have also pointed to a direct ICP-lowering effect of GLP-1RAs
DAllesio, D
